Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

8.7%

2 terminated/withdrawn out of 23 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

17%

4 trials in Phase 3/4

Results Transparency

40%

4 of 10 completed trials have results

Key Signals

2 recruiting4 with results

Enrollment Performance

Analytics

N/A

15(68.2%)

Phase 4

4(18.2%)

Phase 1

2(9.1%)

Phase 2

1(4.5%)

22Total

N/A(15)

Phase 4(4)

Phase 1(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (23)

Showing 20 of 23 trials

NCT05471011Active Not Recruiting

COVID-19 Outcome Prediction Algorithm

Role: collaborator

NCT07325149Not ApplicableNot Yet Recruiting

The Effect of Exoskeletal-assisted Walking Combined With Transcutaneous Spinal Cord Stimulation on Bone Strength.

Role: lead

NCT05708274Phase 1Completed

Pharmacological Agents for Chronic Spinal Cord Injury (SCI)

Role: lead

NCT03851302Not ApplicableCompleted

Effects of Remote Ischemic Conditioning on Hand Use in Individuals With SCI and ALS

Role: lead

NCT06104735Not ApplicableRecruiting

Finding the Best Combination of Brain and Spinal Cord Stimulation With Hand Training After Spinal Cord Injury

Role: lead

NCT06418178Phase 2Recruiting

Dose Optimization of MDMA-Assisted Therapy for PTSD

Role: lead

NCT04727866Not ApplicableCompleted

Brain Plus Spinal Stimulation for Cervical SCI

Role: lead

NCT03414424Not ApplicableCompleted

Non-invasive Cervical Electrical Stimulation for SCI

Role: lead

NCT03806023Not ApplicableTerminated

EMG Triggered Closed-Loop Stimulation for Spinal Cord Injury Individuals

Role: lead

NCT02469675Not ApplicableCompleted

Brain and Nerve Stimulation for Hand Muscles in Spinal Cord Injury and ALS

Role: lead

NCT03076632Not ApplicableWithdrawn

Interactions Between Neurostimulation and Physical Exercise

Role: lead

NCT01525680Not ApplicableUnknown

A Randomized Clinical Trial of Hydrocortisone Augmentation of Prolonged Exposure

Role: lead

NCT01980550Phase 4Completed

Association of Functional COMT Val108/Met Polymorphism With Smoking Cessation in Nicotine Replacement Therapy

Role: collaborator

NCT01354158Phase 1Completed

A Dose Titration of Droxidopa in Patients With Spinal Cord Injury

Role: lead

NCT00762164Phase 4Completed

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol

Role: lead

NCT00762229Not ApplicableCompleted

Evaluation of LDL Cholesterol in Patients Switched From 10 to 5 Milligrams of Zetia (Ezetimibe)

Role: lead

NCT01090518Not ApplicableUnknown

Cortisol Augmentation of a Psychological Treatment in Warfighters With Post Traumatic Stress Disorder (PTSD)

Role: lead

NCT00850447Not ApplicableCompleted

Cognitive Remediation in Posttraumatic Stress Disorder (PTSD)

Role: lead

NCT00972829Phase 4Unknown

Tolerability and Lipid Lowering Effect of Weekly/Biweekly Crestor in Statin Intolerant Patients Treated With Zetia

Role: lead

NCT00469664Phase 4Unknown

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia

Role: collaborator